Latest News

Hollings researcher receives Department of Defense Early Career Scholar Award to improve immune therapies by targeting resistant kidney tumors.

MUSC Hollings researchers find that targeting an immunosuppressive protein on two fronts can reduce metastasis and restore sensitivity to immunotherapy.

Polyploid giant cancer cells, which are monstrously oversized and contain multiple nuclei, could be culprits in disease recurrence after cancer therapy.

Dr. Kevin Roggin, new surgical oncology chief, says he learned how to be a well-rounded physician through good role models, and he wants to pass that along.

Doctors with MUSC Hollings Cancer Center are the first in South Carolina to perform head and neck cancer surgery with the single port da Vinci SP.

Three Hollings members – an M.D., a D.D.S. and a Ph.D. – are pooling their expertise to develop a personalized vaccine to prevent oral cancer from returning.

The Clinical Trialist Training Program offers early-career clinicians the time and know-how to lead clinical trials.

Two small business grants will help Hollings researchers to test new ways to treat acute myeloid leukemia.

Three of this year's TEDxCharleston speakers work for MUSC.

Playing “serious” games can be an effective and engaging way to teach teamwork and other skills to robotic surgery teams.